William Lewis Sells 18,750 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00. Following the completion of the sale, the chief executive officer now directly owns 384,960 shares of the company’s stock, valued at approximately $26,885,606.40. This represents a 4.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

William Lewis also recently made the following trade(s):

• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Stock Performance

Shares of INSM opened at $69.86 on Monday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a one year low of $21.92 and a one year high of $80.53. The company’s fifty day moving average price is $71.62 and its 200 day moving average price is $72.48. The company has a market capitalization of $12.50 billion, a PE ratio of -12.59 and a beta of 1.12.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. The business’s revenue was up 18.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.10) earnings per share. As a group, analysts expect that Insmed Incorporated will post -5.44 earnings per share for the current year.

Institutional Investors Weigh In On Insmed

Hedge funds have recently modified their holdings of the business. V Square Quantitative Management LLC acquired a new position in Insmed during the 3rd quarter valued at $30,000. GAMMA Investing LLC increased its holdings in shares of Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 224 shares during the period. Exchange Traded Concepts LLC raised its position in shares of Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 627 shares during the last quarter. JCIC Asset Management Inc. bought a new stake in shares of Insmed in the third quarter valued at about $133,000. Finally, Quantbot Technologies LP acquired a new stake in Insmed during the third quarter worth about $133,000.

Analysts Set New Price Targets

A number of brokerages recently commented on INSM. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Monday, September 9th. Bank of America upped their price target on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. HC Wainwright reissued a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. upped their target price on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research report on Friday, November 22nd. Finally, Truist Financial reiterated a “buy” rating and set a $105.00 price target (up from $100.00) on shares of Insmed in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.